MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy

Bo Liu; Minxiao Yi; Yang Tang; Qingxu Liu; Hong Qiu; Yanmei Zou; Ping Peng; Lu Zhang; Chunping Hu; Xianglin Yuan

doi:10.18632/oncotarget.12164

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy

Bo Liu, Minxiao Yi, Yang Tang, Qingxu Liu, Hong Qiu, Yanmei Zou, Ping Peng, Lu Zhang, Chunping Hu and Xianglin Yuan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:70175-70184. https://doi.org/10.18632/oncotarget.12164

Metrics: PDF 2000 views | HTML 2588 views | ?

Abstract

Bo Liu1, Minxiao Yi1, Yang Tang1, Qingxu Liu1, Hong Qiu1, Yanmei Zou1, Ping Peng1, Lu Zhang1, Chunping Hu2, Xianglin Yuan1

1Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

2Department of Statistics, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

Correspondence to:

Xianglin Yuan, email: [email protected]

Keywords: single nucleotide polymorphism, radiation-induced lung injury, lung cancer, MMP-1, radiotherapy

Received: April 25, 2016 Accepted: September 14, 2016 Published: September 21, 2016

ABSTRACT

Matrix metalloproteinase-1 (MMP-1) has been implicated in several inflammatory and fibrotic diseases. We hypothesized that genetic variations in the MMP1 promoter region are associated with risk of radiation-induced lung injury (RILI). A cohort of 251 lung cancer patients was genotyped for five single nucleotide polymorphisms in the MMP1 promoter region. We found that rs1144393 AG/GG was strongly correlated with an increased occurrence of grade ≥ 2 RILI (p = 0.002). Additionally, patients with the rs1144393 AG/GG genotypes exhibited higher MMP-1 expression than patients with the AA genotype in lung tissues (n = 28, p = 0.022) and plasma samples (n = 40, p = 0.018). Our results indicated that rs1144393 in the MMP1 promoter region can be a predictor of grade ≥ 2 RILI in lung cancer patients treated with thoracic radiation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12164

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

MMP-1 promoter polymorphism is associated with risk of radiation-induced lung injury in lung cancer patients treated with radiotherapy

Abstract